Replacing acid α-glucosidase in Pompe disease: recombinant and transgenic enzymes are equipotent, but neither completely clears glycogen from type II muscle fibers
Nina Raben(APT Therapeutics (United States)), Paul H. Plötz(National Institutes of Health), Kanneboyina Nagaraju(Children's National), Abigail L. Gilbert(National Institute of Arthritis and Musculoskeletal and Skin Diseases), Deborah de Jong(National Institutes of Health), Tokiko Fukuda(National Institutes of Health), Kunio Nagashima(Science Applications International Corporation (United States)), Beth L. Thurberg(Sanofi (United States)), Robert J. Mattaliano, John J. Hopwood(Women's and Children's Hospital), Peter J. Meikle(Baker Heart and Diabetes Institute)
Cited by 138
Related Papers
Therapy of Lupus Nephritis
|New England Journal of Medicine|1986|1.2k
A New Approach to the Classification of Idiopathic Inflammatory Myopathy
|Medicine|1991|974
Defective Reticuloendothelial System Fc-Receptor Function in Systemic Lupus Erythematosus
|New England Journal of Medicine|1979|531
Enhanced autoantigen expression in regenerating muscle cells in idiopathic inflammatory myopathy
|The Journal of Experimental Medicine|2005|395